BlackRock’s Impact BioMedical IBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$112K Sell
20,024
-574
-3% -$3.36K ﹤0.01% 5088
2026
Q2
$120K Hold
20,598
– – ﹤0.01% 4965
2026
Q1
$156K Hold
20,598
– – ﹤0.01% 4854
2025
Q4
$131K Buy
20,598
+572
+3% +$3.82K ﹤0.01% 4833
2025
Q3
$168K Hold
20,026
– – ﹤0.01% 4716
2025
Q2
$164K Buy
20,026
+17,595
+724% +$125K ﹤0.01% 4717
2025
Q1
$26.7K Buy
+2,431
New +$53.1K ﹤0.01% 5042

Other funds holding IBO

BlackRock's IBO Position: Q3 2026 in Review

BlackRock reduced its Impact BioMedical (IBO) stake by 2.8% in Q3 2026, selling an estimated $3.36K and leaving 20,024 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #5088.

BlackRock first reported a position in IBO in Q1 2025 and has held it in 7 quarters since. The position peaked at $168K in Q3 2025. 19 funds tracked by Wall St. Rank hold IBO as of Q3 2026.

  • BlackRock held 20,024 shares of Impact BioMedical worth $112K as of Q3 2026.
  • BlackRock sold 574 Impact BioMedical shares in Q3 2026, an estimated $3.36K.
  • Impact BioMedical made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #5088 holding.
  • BlackRock first reported a position in Impact BioMedical in Q1 2025 and has held it in 7 quarters since.
  • BlackRock's Impact BioMedical position peaked at $168K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.